Clinical review: the role of biomarkers in the diagnosis and management of community-acquired pneumonia
about
New role of biomarkers: mid-regional pro-adrenomedullin, the biomarker of organ failureIn vivo transcriptional profiling of Yersinia pestis reveals a novel bacterial mediator of pulmonary inflammationBiomarker-guided antibiotic therapy-strengths and limitationsThe effects of age on inflammatory and coagulation-fibrinolysis response in patients hospitalized for pneumoniaHow and when to use common biomarkers in community-acquired pneumoniaEvaluating the evidence for the implementation of C-reactive protein measurement in adult patients with suspected lower respiratory tract infection in primary care: a systematic review.C-reactive protein in critically ill cancer patients with sepsis: influence of neutropenia.Cytokine Concentrations in Plasma from Children with Severe and Non-Severe Community Acquired Pneumonia.Attenuation of Inflammatory Mediators (TNF-α and Nitric Oxide) and Up-Regulation of IL-10 by Wild and Domesticated Basidiocarps of Amauroderma rugosum (Blume & T. Nees) Torrend in LPS-Stimulated RAW264.7 Cells.C-reactive protein, an early marker of community-acquired sepsis resolution: a multi-center prospective observational study.Cervical leukocytes and spontaneous preterm birth.Biomarker kinetics in the prediction of VAP diagnosis: results from the BioVAP study.Biomarker-enhanced triage in respiratory infections: a proof-of-concept feasibility trial.Diagnostic accuracy of lung ultrasonography combined with procalcitonin for the diagnosis of pneumonia: a pilot study.Exhaled Breath Metabolomics for the Diagnosis of Pneumonia in Intubated and Mechanically-Ventilated Intensive Care Unit (ICU)-Patients.Early diagnosis of sepsis using serum biomarkers.Procalcitonin-guided antibiotic treatment of respiratory tract infections in a primary care setting: are we there yet?Year in review 2010: Critical Care--Infection.The role of procalcitonin in respiratory infections.Biomarker-guided antibiotic therapy in adult critically ill patients: a critical review.Pseudomonas aeruginosa treatment and transmission reduction.Biomarkers for community-acquired pneumonia in the emergency department.Pros and cons of using biomarkers versus clinical decisions in start and stop decisions for antibiotics in the critical care setting.Personalized treatment of severe pneumonia in cancer patients.BDMC33, A curcumin derivative suppresses inflammatory responses in macrophage-like cellular system: role of inhibition in NF-κB and MAPK signaling pathways.Gram-negative and Gram-positive bacterial infections give rise to a different metabolic response in a mouse modelSoluble thrombomodulin to evaluate the severity and outcome of community-acquired pneumonia.Pro-adrenomedullin as a novel biomarker for predicting infections and response to antimicrobials in febrile patients with hematologic malignancies.Adrenomedullin is a useful biomarker for the prognosis of critically ill septic children.Utility of two biomarkers for directing care among patients with non-severe community-acquired pneumonia.Plasma midregional proadrenomedullin in newborn infants: impact of prematurity and perinatal infection.Serum CRP protein as a differential marker in cancer.Procalcitonin for antibiotic treatment in intensive care unit patients.Prognostic performance of MR-pro-adrenomedullin in patients with community acquired pneumonia in the Emergency Department compared to clinical severity scores PSI and CURB.Management of community-acquired pneumonia in immunocompetent adults: updated Swedish guidelines 2017.The Role of Serum Coagulation Factors in the Differential Diagnosis of Patients with Pneumonia and Parapneumonic Effusion.Differences in inflammatory marker patterns for adult community-acquired pneumonia patients induced by different pathogens.Is genomic medicine finally coming of age for the diagnosis of pneumonia?Metabolic profiles in community-acquired pneumonia: developing assessment tools for disease severity.Association of serum procalcitonin and C-reactive protein levels with CURB-65 criteria among patients with community-acquired pneumonia.
P2860
Q28076596-6D8E1A48-D37A-4D60-98B2-AEB8D539B6BAQ30371862-0133361D-6F07-4CCE-B93D-82C2EA48FF38Q33747590-9D3DE4D3-0FEE-4C16-BD27-D45E6E56161AQ33749744-C4371D8B-375B-4954-AD6F-7B2EA2BD164BQ33801313-89B2B102-6332-441A-8CB9-351E0D8C676EQ34096701-D90E4106-B177-43AB-BF0C-9452C613D204Q35558248-F4126C3A-2791-4054-B502-EC1C3EFCA7DCQ35788577-FC2727CC-4DDB-48A9-9DE2-7A3541B64834Q35795412-0C01CF5D-7F2C-447F-84FC-6A6973A1DF69Q36070410-8DB0FEBF-1051-4211-98FB-1E1155C796F5Q36610270-F1192BE8-253B-463C-A165-156E11884E71Q36795684-1109D855-85C4-4453-8E72-69C890B51378Q37209299-34F8896A-85D5-4DA7-85B0-BD37B7EC4912Q37405242-B1809395-2DB9-413F-8283-7798422EEFB0Q37691060-1F8EB302-B6CA-4733-BC47-1055197A34C9Q37894737-B9825CC8-C3B9-4D4C-B024-07B4DD88A849Q37910003-157DFBAB-C03C-423E-86C5-4259A05BF709Q37966018-F232972D-5E8C-4912-A4F7-C1B7D87787BCQ37989831-DFB2000B-0F08-4E29-841A-8B6445CB055AQ38028687-555429D5-B2F7-40BC-8C23-CD2C2DF87B28Q38131538-C40C118E-8CB6-439D-89B1-0E00568C1000Q38263097-97002785-AACF-4C71-9FA7-1B1149FC9CB4Q38550893-273C869F-F35C-4759-A2A8-775438090572Q38613281-4A7019B0-C812-4F4D-B123-30E4C201D2ABQ39367047-08A72FAD-B2EC-4A18-B51E-C2986E91DCA3Q39631903-D260BE7B-DBCF-4FCF-9E95-87B33F6712C3Q40173806-BDFF064B-CC9D-480E-ADE4-4D850D5F8CB6Q40262183-8D8E0101-1467-492E-95C6-23D3588FF439Q41658608-2CEE0F4E-EBC1-4690-9903-2BDFC3D154A7Q43965327-A6F4B46D-6594-4FB8-8050-0158C925692FQ45235089-D4D8733F-3C0E-4D2F-83EF-CDD5D23E2657Q46155576-905192B5-BC6F-41D3-B7A9-D80D06792EBCQ46478127-A9E82FB2-5D72-4664-AEA4-4D0C1B2D9366Q47159484-EC293E4C-86DF-4AE6-B0EE-A122A8366B3CQ47627293-CD32564D-5F5F-4795-A9EA-D93DF43FED5FQ51046879-3DB4AD72-6D7F-4802-83EB-788B251483F8Q51160587-26B6F614-738B-4B22-9E7F-243B0D1AF7A9Q54754725-1C5C9339-07D6-4C6C-97FC-70C9D34D8C85Q55069453-AEC65682-0A55-40C3-BC01-0036E8DAA9B8Q55255135-43566BF6-5FB3-45B1-8A85-03D39106F0DE
P2860
Clinical review: the role of biomarkers in the diagnosis and management of community-acquired pneumonia
description
2010 nî lūn-bûn
@nan
2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
name
Clinical review: the role of b ...... f community-acquired pneumonia
@ast
Clinical review: the role of b ...... f community-acquired pneumonia
@en
Clinical review: the role of b ...... f community-acquired pneumonia
@en-gb
Clinical review: the role of b ...... f community-acquired pneumonia
@nl
type
label
Clinical review: the role of b ...... f community-acquired pneumonia
@ast
Clinical review: the role of b ...... f community-acquired pneumonia
@en
Clinical review: the role of b ...... f community-acquired pneumonia
@en-gb
Clinical review: the role of b ...... f community-acquired pneumonia
@nl
prefLabel
Clinical review: the role of b ...... f community-acquired pneumonia
@ast
Clinical review: the role of b ...... f community-acquired pneumonia
@en
Clinical review: the role of b ...... f community-acquired pneumonia
@en-gb
Clinical review: the role of b ...... f community-acquired pneumonia
@nl
P2860
P921
P3181
P356
P1433
P1476
Clinical review: the role of b ...... f community-acquired pneumonia
@en
P2093
Steven M Opal
P2860
P2888
P3181
P356
10.1186/CC8155
P407
P577
2010-02-08T00:00:00Z
P5875
P6179
1029288959